Xiao D - Search Results

1

Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.

Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, Zhang H, Yan Y, Zhao L, Li W, Zhang T, Xiao D, Guo X, Li Y, Yang J, Hu Z, Wang M, Zhong W. Cao R, et al. Among authors: xiao d. ACS Infect Dis. 2020 Sep 11;6(9):2524-2531. doi: 10.1021/acsinfecdis.0c00522. Epub 2020 Aug 18. ACS Infect Dis. 2020. PMID: 32786284

2

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy.

Wang Y, Fan S, Xiao D, Xie F, Li W, Zhong W, Zhou X. Wang Y, et al. Among authors: xiao d. Cancers (Basel). 2019 Jul 8;11(7):957. doi: 10.3390/cancers11070957. Cancers (Basel). 2019. PMID: 31288450 Free PMC article.

3

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib.

Li J, Xiao D, Liu L, Xie F, Li W, Sun W, Yang X, Zhou X. Li J, et al. Among authors: xiao d. Molecules. 2020 Jan 18;25(2):407. doi: 10.3390/molecules25020407. Molecules. 2020. PMID: 31963730 Free PMC article.

4

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.

Wang Y, Liu L, Fan S, Xiao D, Xie F, Li W, Zhong W, Zhou X. Wang Y, et al. Among authors: xiao d. Cancers (Basel). 2020 Mar 21;12(3):744. doi: 10.3390/cancers12030744. Cancers (Basel). 2020. PMID: 32245171 Free PMC article.

5

Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.

Fan S, Xiao D, Wang Y, Liu L, Zhou X, Zhong W. Fan S, et al. Among authors: xiao d. Future Med Chem. 2020 Sep;12(17):1565-1578. doi: 10.4155/fmc-2020-0158. Epub 2020 Jul 8. Future Med Chem. 2020. PMID: 32638628 Free PMC article. Review.

6

A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.

Xiao D, Zhao L, Xie F, Fan S, Liu L, Li W, Cao R, Li S, Zhong W, Zhou X. Xiao D, et al. Theranostics. 2021 Jan 1;11(6):2550-2563. doi: 10.7150/thno.51232. eCollection 2021. Theranostics. 2021. PMID: 33456559 Free PMC article.

7

Novel antibody-drug conjugate with UV-controlled cleavage mechanism for cytotoxin release.

Li J, Xiao D, Xie F, Li W, Zhao L, Sun W, Yang X, Zhou X. Li J, et al. Among authors: xiao d. Bioorg Chem. 2021 Jun;111:104475. doi: 10.1016/j.bioorg.2020.104475. Epub 2020 Nov 16. Bioorg Chem. 2021. PMID: 33798843

8

From prodrug to pro-prodrug: hypoxia-sensitive antibody-drug conjugates.

Wang Y, Xiao D, Li J, Fan S, Xie F, Zhong W, Zhou X, Li S. Wang Y, et al. Among authors: xiao d. Signal Transduct Target Ther. 2022 Jan 21;7(1):20. doi: 10.1038/s41392-021-00833-8. Signal Transduct Target Ther. 2022. PMID: 35058439 Free PMC article. No abstract available.

9

Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins.

Yan Y, Yang J, Xiao D, Yin J, Song M, Xu Y, Zhao L, Dai Q, Li Y, Wang C, Wang Z, Ren X, Yang X, Ni J, Liu M, Guo X, Li W, Chen X, Liu Z, Cao R, Zhong W. Yan Y, et al. Among authors: xiao d. Antiviral Res. 2022 Jun;202:105325. doi: 10.1016/j.antiviral.2022.105325. Epub 2022 Apr 20. Antiviral Res. 2022. PMID: 35460703 Free article.

10

Improvement of the C-glycosylation Step for the Synthesis of Remdesivir.

Xue F, Zhou X, Zhou R, Zhou X, Xiao D, Gu E, Guo X, Xiang J, Wang K, Yang L, Zhong W, Qin Y. Xue F, et al. Among authors: xiao d. Org Process Res Dev. 2020 Aug 5;24(9):1772-1777. doi: 10.1021/acs.oprd.0c00310. eCollection 2020 Sep 18. Org Process Res Dev. 2020. PMID: 37556261

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,614 results

Search Page